With key test still looming, Celgene and Acceleron nab FDA okay for beta-thalassemia med
While pricing concerns continue to cloud the future of bluebird bio’s gene therapy fix, the FDA has given its okay for Celgene and Acceleron’s beta-thalassemia drug Reblozyl — to treat anemia in adults who require regular transfusions. An approval for myelodysplastic syndromes (MDS) — which will likely determine if the drug is a major commercial success — is still under review.
The drug will be priced at $3,441 per 25 mg vial, Acceleron said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.